Frazier Life Sciences Management
ABVX icon

Frazier Life Sciences Management’s Abivax ABVX Stock Holding History

Frazier Life Sciences Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-378,300
Closed -$51M – 39
2025
Q4 		$51M Hold
378,300
– – 1.37% 20
2025
Q3 		$32.1M Buy
+378,300
New +$23.2M 0.96% 22

Other funds holding ABVX

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

Frazier Life Sciences Management's ABVX Position: Q1 2026 in Review

Frazier Life Sciences Management sold out of Abivax (ABVX) in Q1 2026, closing a stake of 378,300 shares — an estimated $51M sold.

Frazier Life Sciences Management first reported a position in ABVX in Q3 2025 and held it in 2 quarters. The position peaked at $51M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Frazier Life Sciences Management reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Frazier Life Sciences Management sold 378,300 Abivax shares in Q1 2026, an estimated $51M.
  • Frazier Life Sciences Management first reported a position in Abivax in Q3 2025 and held it in 2 quarters.
  • Frazier Life Sciences Management's Abivax position peaked at $51M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.